Kotak Alternate Asset Managers Limited (KAAML) has invested Rs 1,445 crore ($173 million) to part-finance Matrix Pharma’s acquisition of the active pharmaceutical ingredients (API) business of Viatris. The investment has been made through the Strategic Situations Fund II of KAAML, according to a statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
